Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)

被引:6
作者
Baron-Hay, Sally [1 ]
Aapro, Matti [2 ]
Bernareggi, Alberto [3 ]
Schwartzberg, Lee [4 ]
机构
[1] Royal North Shore Hosp, St Leonards, NSW, Australia
[2] Genolier Canc Ctr, Clin Genolier, Genolier, Switzerland
[3] Helsinn Healthcare SA, Lugano, Switzerland
[4] West Canc Ctr, Memphis, TN USA
关键词
Chemotherapy-induced nausea and vomiting; CINV; NEPA; Netupitant; Palonosetron; Administration timing; 5-HT3 RECEPTOR ANTAGONISTS; PLACEBO-CONTROLLED TRIAL; CISPLATIN-INDUCED EMESIS; FIXED-DOSE COMBINATION; DELAYED EMESIS; DOUBLE-BLIND; PHASE-III; EFFICACY; SAFETY; APREPITANT;
D O I
10.1007/s00520-019-4640-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe administration timing of antiemetic and chemotherapeutic regimens is often determined by regulatory indications, based on registration studies. Oral NEPA, fixed combination of the neurokinin-1 receptor antagonist (NK(1)RA) netupitant and the 5-hydroxytryptamine-3 RA (5-HT(3)RA) palonosetron, is recommended to be administered approximately 60min before chemotherapy. Reducing chair time for chemotherapy administration at oncology day therapy units would improve facility efficiency without compromising patient symptom management. The objective was to determine if oral NEPA can be administered closer to chemotherapy initiation without compromising patient symptom management.MethodsNK(1) receptor occupancy (NK1RO) time course in the brain was determined using positron emission tomography; netupitant and palonosetron plasma concentration-time profiles were described by pharmacokinetic (PK) models; and the rate, extent, and duration of RO by netupitant and palonosetron were predicted by pharmacodynamic modeling. Clinical efficacy data from a pivotal study in cisplatin and oral NEPA-receiving patients were reviewed in the context of symptom management.ResultsStriatal 90% NK1RO, assumed to correlate with NK(1)RA antiemetic efficacy, was predicted at netupitant plasma concentration of 225ng/mL, reached at 2.23h following NEPA administration. Palonosetron 90% 5-HT3RO was predicted at a 188-ng/L plasma concentration, reached at 1.05h postdose. The mean time to first treatment failure for the 1.5% of NEPA-treated patients without complete response receiving highly emetogenic chemotherapy was 8h. Antiemetic efficacy was sustained over 5days despite the expected decrease of NK1RO and 5-HT3RO.ConclusionsResults suggest that administering oral NEPA closer to initiation of cisplatin administration would provide similar antiemetic efficacy. Prospective clinical validation is required.
引用
收藏
页码:1309 / 1317
页数:9
相关论文
共 34 条
[1]   A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy [J].
Aapro, M. ;
Rugo, H. ;
Rossi, G. ;
Rizzi, G. ;
Borroni, M. E. ;
Bondarenko, I. ;
Sarosiek, T. ;
Oprean, C. ;
Cardona-Huerta, S. ;
Lorusso, V. ;
Karthaus, M. ;
Schwartzberg, L. ;
Grunberg, S. .
ANNALS OF ONCOLOGY, 2014, 25 (07) :1328-1333
[2]  
[Anonymous], 2018, NCCN Clinical Practice Guidelines in Oncology
[3]  
[Anonymous], 2018, AK NET PAL PRESCR IN
[4]   Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment [J].
Basch, Ethan ;
Deal, Allison M. ;
Dueck, Amylou C. ;
Scher, Howard I. ;
Kris, Mark G. ;
Hudis, Clifford ;
Schrag, Deborah .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (02) :197-198
[5]   Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial [J].
Basch, Ethan ;
Deal, Allison M. ;
Kris, Mark G. ;
Scher, Howard I. ;
Hudis, Clifford A. ;
Sabbatini, Paul ;
Rogak, Lauren ;
Bennett, Antonia V. ;
Dueck, Amylou C. ;
Atkinson, Thomas M. ;
Chou, Joanne F. ;
Dulko, Dorothy ;
Sit, Laura ;
Barz, Allison ;
Novotny, Paul ;
Fruscione, Michael ;
Sloan, Jeff A. ;
Schrag, Deborah .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) :557-+
[6]   Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant [J].
Bergström, M ;
Hargreaves, RJ ;
Burns, HD ;
Goldberg, MR ;
Sciberras, D ;
Reines, SA ;
Petty, KJ ;
Ögren, M ;
Antoni, G ;
Långström, B ;
Eskola, O ;
Scheinin, M ;
Solin, O ;
Majumdar, AK ;
Constanzer, ML ;
Battisti, WP ;
Bradstreet, TE ;
Gargano, C ;
Hietala, J .
BIOLOGICAL PSYCHIATRY, 2004, 55 (10) :1007-1012
[7]   Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists [J].
Bosnjak, Snezana M. ;
Gralla, Richard J. ;
Schwartzberg, Lee .
SUPPORTIVE CARE IN CANCER, 2017, 25 (05) :1661-1671
[8]   Evaluation of the Effect of Food and Age on the Pharmacokinetics of Oral Netupitant and Palonosetron in Healthy Subjects: A Randomized, Open-Label, Crossover Phase 1 Study [J].
Calcagnile, Selma ;
Lanzarotti, Corinna ;
Gutacker, Michaela ;
Jakob-Rodamer, Verena ;
Kammerer, Klaus Peter ;
Timmer, Wolfgang .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (05) :377-386
[9]   Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? - Systematic re-evaluation of clinical evidence and drug cost implications [J].
Geling, O ;
Eichler, HG .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1289-1294
[10]   A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy [J].
Gralla, R. J. ;
Bosnjak, S. M. ;
Hontsa, A. ;
Balser, C. ;
Rizzi, G. ;
Rossi, G. ;
Borroni, M. E. ;
Jordan, K. .
ANNALS OF ONCOLOGY, 2014, 25 (07) :1333-1339